Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Carbon dioxide intranasal - Soleno Therapeutics

Next Previous
X
Search
Drug Profile

Carbon dioxide intranasal - Soleno Therapeutics

Alternative Names: Serenz; Serenz Allergy Relief

Latest Information Update: 06 Nov 2021

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Capnia
  • Developer Soleno Therapeutics
  • Class Inorganic carbon compounds; Oxides
  • Mechanism of Action Calcitonin gene-related peptide antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Trigeminal neuralgia
  • New Molecular Entity No

Highest Development Phases

  • Phase II Allergic rhinitis; Cluster headache; Trigeminal neuralgia

Most Recent Events

  • 29 Aug 2019 Carbon dioxide intranasal is still in phase II trials for Allergic rhinitis, Cluster headache and Trigeminal neuralgia in USA (Capnia website, August 2019)
  • 12 Apr 2017 Capnia terminates a phase II trial in Cluster headache in USA (Intranasal) (NCT02381795)
  • 13 May 2016 9195736 - added trial Phase II TN description

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top